S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
The single greatest medical breakthrough of all time? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
The single greatest medical breakthrough of all time? (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
The single greatest medical breakthrough of all time? (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A fight over precious groundwater in a rural California town is rooted in carrots
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
The single greatest medical breakthrough of all time? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
The single greatest medical breakthrough of all time? (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
The single greatest medical breakthrough of all time? (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A fight over precious groundwater in a rural California town is rooted in carrots
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
The single greatest medical breakthrough of all time? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
The single greatest medical breakthrough of all time? (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
The single greatest medical breakthrough of all time? (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A fight over precious groundwater in a rural California town is rooted in carrots
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
The single greatest medical breakthrough of all time? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
The single greatest medical breakthrough of all time? (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
The single greatest medical breakthrough of all time? (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A fight over precious groundwater in a rural California town is rooted in carrots
NASDAQ:NVCR

NovoCure (NVCR) Stock Forecast, Price & News

$16.15
-0.48 (-2.89%)
(As of 09/29/2023 ET)
Compare
Today's Range
$16.06
$16.79
50-Day Range
$16.15
$40.34
52-Week Range
$16.06
$120.03
Volume
1.99 million shs
Average Volume
1.48 million shs
Market Capitalization
$1.72 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.38

NovoCure MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
224.3% Upside
$52.38 Price Target
Short Interest
Healthy
7.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.15
Upright™ Environmental Score
News Sentiment
0.57mentions of NovoCure in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$31,639 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.07) to ($2.08) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

227th out of 971 stocks

Surgical & Medical Instruments Industry

31st out of 100 stocks


NVCR stock logo

About NovoCure (NASDAQ:NVCR) Stock

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

NVCR Price History

NVCR Stock News Headlines

Biden's Digital Dollar Nightmare
On July 20th, 2023, the Federal Reserve launched FedNow, which could spark the fuse for a Digital Dollar. If a Digital Dollar happens, the government could: Monitor every transaction, keep track of your spending habits, and potentially control your individual choices… Which MAY steal your freedoms in one way or another. And if you don’t plan for this now... Your retirement savings could be at risk of being frozen, hacked, or deleted. You’ll want to act fast... Because with Biden’s long history of voting against Americans... Who knows how much longer until Biden strikes again! Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late!
Should You Hold NovoCure Limited (NVCR)?
Down 31% in 1 Day, What's Next for NovoCure Stock?
Why Novocure Stock Fell 24.4% This Week
New gold-backed currency could kill the Dollar
Rumors are circulating of a new currency that will be backed by gold. A huge story, if true. And while it’s impossible to know how it will pan out, there’s one important move you should make right now, before this happens. It’s the best way to protect your wealth today. Because if you’re not careful, YOU could be the one who pays the price
What 11 Analyst Ratings Have To Say About NovoCure
What's Going On With NovoCure Stock Today?
Why Is Novocure (NVCR) Stock Down 30% Today?
Could NovoCure Stock Help You Become a Millionaire?
See More Headlines
Receive NVCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.

NVCR Company Calendar

Last Earnings
7/27/2023
Today
10/01/2023
Next Earnings (Estimated)
10/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVCR
Fax
N/A
Employees
1,320
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$52.38
High Stock Price Forecast
$102.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+224.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-92,530,000.00
Pretax Margin
-31.71%

Debt

Sales & Book Value

Annual Sales
$537.84 million
Book Value
$4.20 per share

Miscellaneous

Free Float
100,571,000
Market Cap
$1.72 billion
Optionable
Optionable
Beta
0.62
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. William F. DoyleMr. William F. Doyle (Age 61)
    Exec. Chairman
    Comp: $1.52M
  • Mr. Asaf DanzigerMr. Asaf Danziger (Age 57)
    Pres, CEO & Director
    Comp: $1.7M
  • Ms. Ashley CordovaMs. Ashley Cordova (Age 43)
    Chief Financial Officer
    Comp: $933.39k
  • Mr. Wilhelmus C. M. GroenhuysenMr. Wilhelmus C. M. Groenhuysen (Age 65)
    Chief Operating Officer
    Comp: $1.01M
  • Mr. Pritesh ShahMr. Pritesh Shah (Age 44)
    Chief Growth Officer
    Comp: $810.6k
  • Mr. Frank LeonardMr. Frank Leonard
    Pres of CNS Cancers U.S.
  • Prof. Yoram Palti M.D. (Age 85)
    Ph.D., Founder & CTO
  • Dr. Moshe Giladi Ph.D.
    Chief Science Officer
  • Ms. Ingrid Goldberg
    VP of Investor Relations
  • Mr. Barak Ben Arye (Age 47)
    Gen. Counsel













NVCR Stock - Frequently Asked Questions

Should I buy or sell NovoCure stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NVCR shares.
View NVCR analyst ratings
or view top-rated stocks.

What is NovoCure's stock price forecast for 2023?

9 equities research analysts have issued 12 month price objectives for NovoCure's stock. Their NVCR share price forecasts range from $25.00 to $102.00. On average, they predict the company's share price to reach $52.38 in the next twelve months. This suggests a possible upside of 224.3% from the stock's current price.
View analysts price targets for NVCR
or view top-rated stocks among Wall Street analysts.

How have NVCR shares performed in 2023?

NovoCure's stock was trading at $73.35 at the start of the year. Since then, NVCR stock has decreased by 78.0% and is now trading at $16.15.
View the best growth stocks for 2023 here
.

Are investors shorting NovoCure?

NovoCure saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 7,580,000 shares, a decrease of 17.7% from the August 31st total of 9,210,000 shares. Based on an average daily trading volume, of 1,760,000 shares, the short-interest ratio is presently 4.3 days. Approximately 7.9% of the company's shares are short sold.
View NovoCure's Short Interest
.

When is NovoCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our NVCR earnings forecast
.

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) issued its quarterly earnings results on Thursday, July, 27th. The medical equipment provider reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.04. The medical equipment provider earned $126.05 million during the quarter, compared to analysts' expectations of $124.25 million. NovoCure had a negative net margin of 34.35% and a negative trailing twelve-month return on equity of 40.21%. The firm's quarterly revenue was down 10.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.23) earnings per share.

What is Asaf Danziger's approval rating as NovoCure's CEO?

17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees.

What other stocks do shareholders of NovoCure own?
What is NovoCure's stock symbol?

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

How do I buy shares of NovoCure?

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NovoCure's stock price today?

One share of NVCR stock can currently be purchased for approximately $16.15.

How much money does NovoCure make?

NovoCure (NASDAQ:NVCR) has a market capitalization of $1.72 billion and generates $537.84 million in revenue each year. The medical equipment provider earns $-92,530,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

How many employees does NovoCure have?

The company employs 1,320 workers across the globe.

How can I contact NovoCure?

NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The official website for the company is www.novocure.com. The medical equipment provider can be reached via phone at 441534756700 or via email at investorinfo@novocure.com.

This page (NASDAQ:NVCR) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -